Drug development in advanced colorectal cancer: Challenges and opportunities

Current Oncology Reports

Volumn 11, Issue 3, 2009, Pages 175-185

  Kelley, Robin K ^a   Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; B RAF KINASE; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GDC 0449; IMATINIB; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MK 0752; NOTCH RECEPTOR; OXALIPLATIN; PANITUMUMAB; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOXICITY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HUMAN; LUNG CANCER; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DRUG DESIGN; GROWTH INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65349190529     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0026-2     Document Type: Review

References (79)

1. World Health Organization: Cancer. Fact sheet no. 297. Available at http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed November 22, 2008.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-2342.
3. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23: 3502-3508.
4. Kabbinavar FF, Hambleton J, Mass RD, et al.: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23: 3706-3712.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357: 2040-2048.
6. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201-1208.
7. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337-345.
8. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25: 1658-1664.
9. Chung KY, Shia J, Kemeny NE, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23: 1803-1810.
10. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26: 1626-1634.
11. Bokemeyer C, Bondarenko I, Hartmann J, et al.: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [abstract]. J Clin Oncol 2008, 26(Suppl 15): 4000a.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359: 1757-1765.
13. Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26: 374-379.
14. van Cutsem E Lang I, D'Haens G, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract]. J Clin Oncol 2008, 26(Suppl 15): 2.
15. Di Nicolantonio F, Martini M, Molinari F, et al.: Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26: 5705-5712.
16. Schrag D: The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004, 351: 317-319.
17. DiMasi JA, Hansen RN, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22: 151-185.
18. Dimasi JA: Risks in new dAug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001, 69: 297-307.
19. Roberts TG Jr, Lynch TJ Jr, Chabner BA: The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision. J Clin Oncol 2003, 21: 3683-3695.
20. US Food and Drug Administration, US Department of Health and Human Services: Critical Path Report. Bethesda, MD: US Department of Health and Human Services; 2004.
21. US Food and Drug Administration, US Department of Health and Human Services: Critical Path Opportunities Report. Bethesda, MD: US Department of Health and Human Services; 2006.
22. Kopetz S, Overman M, Chang DZ, et al.: Systematic survey of therapeutic trials for metastatic colorectal cancer: Room for improvement in the critical pathway. J Clin Oncol 2008, 26: 2000-2005.
23. Marshall JL, Gehan EA: The development of novel agents for the treatment of colorectal cancer: A critical review of current practice and some suggestions for the future. Clin Adv Hematol Oncol 2007, 5: 167-172.
24. Roberts TG Jr, Chabner BA: Beyond fast track for drug approvals. N Engl J Med 2004, 351: 501-505.
25. Freeman DJ, Juan T, Reiner M, et al.: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008, 7: 184-190.
26. Perez-Soler R: Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006, 8(Suppl 1): S7-S14.
27. Scartozzi M, Galizia E, Chiorrini S, et al.: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20: 227-230.
28. Tejpar S, Peeters M, Humblet Y, et al.: Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data [abstract]. J Clin Oncol 2007, 25(Suppl 15): 4037.
29. Stadler W: Tumor burden endpoints and phase II clinical trial design. In ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2008:89-93.
30. Benjamin RS, Choi H, Macapinlac HA, et al.: We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25: 1760-1764.
31. Cohen SJ, Punt CJ, Iannotti N, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26: 3213-3221.
32. Harkin DP: Genomics and the impact of new technologies on the management of colorectal cancer. Oncologist 2006, 11: 988-991.
33. Carmichael J, Popiela T, Radstone D, et al.: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20: 3617-3627.
34. Douillard JY, Hoff PM, Skillings JR, et al.: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20: 3605-3616.
35. Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 2002, 7: 288-323.
36. Jeung HC, Rha SY, Cho BC, et al.: A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006, 95: 1637-1641.
37. Giovannetti E, Backus HH, Wouters D, et al.: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007, 96: 769-775.
38. Scalamogna R, Brugnatelli S, Tinelli C, et al.: UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. Oncology 2007, 72: 267-273.
39. Lopez-Barcons LA, Zhang J, Siriwitayawan G, et al.: The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. Neoplasia 2004, 6: 457-467.
40. Messerer CL, Ramsay EC, Waterhouse D, et al.: Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004, 10: 6638-6649.
41. Batist G, Sawyer M, Gabrail N, et al.: A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC) [abstract]. J Clin Oncol 2008, 26(Suppl 15): 4108.
42. Alchemia receives an open IND for HA-irinotecan from the U.S. FDA [press release]. Available at http://www.alchemia.com.au/IRM/Company/ShowPage.aspx?CPID= 1341&PageName=FDA%20approves%20open%20IND%20for%20HA- Irinotecan%20phase%203. Accessed December 2, 2008.
43. Saltz LB, Rosen LS, Marshall JL, et al.: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007, 25: 4793-4799.
44. Bhide RS, Cai ZW, Zhang YZ, et al.: Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl pyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006, 49: 2143-2146.
45. Cai ZW, Zhang Y, Borzilleri RM, et al.: Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo [2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008, 51: 1976-1980.
46. Garrett CR Siu L, El-Khoueiry AB, et al.: A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy [abstract]. J Clin Oncol 2008, 26(Suppl 15): 4111.
47. Jonker DJ Rosen LS, Sawyer M, et al.: A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings [abstract]. J Clin Oncol 2007, 25(Suppl 18): 3559.
48. ReinacheA-Schick A, Pohl M, Schmiegel W: Drug insight: antiangiogenic therapies for gastrointestinal cancers-focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol 2008, Aug 12. [Epub ahead of print.]
49. Rocha-Lima CM, Soares HP, Raez LE, Singal R: EGFR targeting of solid tumors. Cancer Control 2007, 14: 295-304.
50. Reedijk M, Odorcic S, Zhang H, et al.: Activation of notch signaling in human colon adenocarcinoma. Int J Oncol 2008, 33: 1223-1229.
51. van Es JH, van Gijn ME, Riccio O, et al.: Notch/gammasecretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435: 959-963.
52. Krop IE Kosh M, Fearen I, et al.: Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors [abstract]. J Clin Oncol 2006, 24(Suppl 18): 10574.
53. Oku Y, Shimoji T, Takifuji K, et al.: Identification of the molecular mechanisms for dedifferentiation at the invasion front of colorectal cancer by a gene expression analysis. Clin Cancer Res 2008, 14: 7215-7222.
54. van den Brink GR, Hardwick JC: Hedgehog Wnteraction in colorectal cancer. Gut 2006, 55: 912-914.
55. van Es JH, Clevers H: Notch and wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005, 11: 496-502.
56. BeEnards R: Cancer: entangled pathways. Nature 2008, 455: 479-480.
57. LoRusso PM Rudin CM, Borad MJ, et al.: A first-in-human, first-in-class, phase I study of systemic hedgehog pathway antagonist, GDC-0449 in patients with advanced solid tumors [abstract]. J Clin Oncol 2008, 26(Suppl 15): 3516.
58. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2: 489-501.
59. Ross JS Qian J, Sheehan C, et al.: Elevated phosphorylated mammalian target of rapamycin (p-mtor) expression in human neoplasms. J Clin Oncol 2007, 25(Suppl 18): 10571.
60. Tabernero J, Rojo F, Calvo E, et al.: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26: 1603-1610.
61. Miller BS, Yee D: Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005, 65: 10123-10127.
62. Zhang Y: Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells. Cancer Invest 2008, 26: 230-236.
63. Piao W, Wang Y, Adachi Y, et al.: Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008, 7: 1483-1493.
64. Cunningham MP, Thomas H, Marks C, et al.: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 2008, 33: 1107-1113.
65. Haluska P, Shaw H, Batzel GN, et al.: Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors [abstract]. J Clin Oncol 2007, 25(Suppl 18): 3586.
66. Lam AK, Ong K, Ho YH: Aurora kinase expression in colorectal adenocarcinoma: Correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol 2008, 39: 599-604.
67. Nishida N, Nagasaka T, Kashiwagi K, et al.: High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007, 6: 525-533.
68. Wilkinson RW, Odedra R, Heaton SP, et al.: AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007, 13: 3682-3688.
69. De Jonge M, Steeghs N, Verwiej J, et al.: Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on days 1, 8, 15 every 4 wks in patients with advanced solid tumors [abstract]. J Clin Oncol 2008, 26(Suppl 15): 3554.
70. Schellens JH, Boss D, Witteveen PO, et al.: Phase I and pharmacologic study of the novel aurora kinase inhibitor AZD1152. J Clin Oncol 2006, 24(Suppl 18): 3008.
71. Eng C, Kindler HL, Nattam S, et al.: A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004, 15: 928-932.
72. Bedi A, Pasricha PJ, Akhtar AJ, et al.: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995, 55: 1811-1816.
73. Ravi R, Jain AJ, Schulick RD, et al.: Elimination of hepatic metastases of colon cancer cells via p53-independent crosstalk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004, 64: 9105-9114.
74. Ogawa S, Nagao M, Kanehiro H, et al.: The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma. Anticancer Res 2004, 24: 1569-1579.
75. Yada A, Yazawa M, Ishida S, et al.: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008, 19: 1060-1067.
76. Laguinge LM, Samara RN, Wang W, et al.: DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 2008, 68: 909-917.
77. Bergsland EK, Ko AH, Tempero MA, et al.: Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol 2008, 26(Suppl 15): 14620.
78. Sharma RA, Van Hazel GA, Morgan B, et al.: Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25: 1099-1106.
79. Toubaji A, Achtar M, Provenzano M, et al.: Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008, 57: 1413-1420.